Trial Profile
A Randomized, Double-blind, Placebo- and Positive-controlled, Multiple-dose, Four-way, Cross-over Study to Evaluate the Effects of Repeated Oral Doses of JNJ-54861911 on Electrocardiogram Intervals in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2018
Price :
$35
*
At a glance
- Drugs Atabecestat (Primary) ; Moxifloxacin
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 05 Mar 2018 Results of analysis assessing potential QT effects of JNJ-54861911 using patient data from NCT01827982, NCT02152332 and NCT01887535 trials published in the Journal of Clinical Pharmacology
- 23 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 04 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.